Plant ID: NPO27018
Plant Latin Name: Cynomorium songaricum
Taxonomy Genus: Cynomorium
Taxonomy Family: Cynomoriaceae
NCBI TaxonomyDB:
627609
Plant-of-the-World-Online:
n.a.
China
FFAR1; FFAR4; ADRA2B; | |
NPSR1; | |
ALPL; RECQL; PGD; ALOX12; HSD17B10; ALOX15; NOX4; POLB; | |
BCL2; | |
MET; FLT3; CDK1; PIM1; AXL; KDR; IGF1R; AURKB; | |
CA2; CA14; CA7; | |
PPARA; | |
RORC; | |
NR1H4; | |
KDM4E; | |
NFKB1; | |
FUT7; | |
LMNA; FABP3; FABP4; FABP5; |
Cytochrome P450 Enzymes: | CYP1B1; |
---|
Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
---|---|---|---|---|
Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
Enzyme_unclassified | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | P05186 | CHEMBL5979 |
Enzyme_unclassified | RECQL | ATP-dependent DNA helicase Q1 | P46063 | CHEMBL1293236 |
Enzyme_unclassified | PGD | 6-phosphogluconate dehydrogenase | P52209 | CHEMBL3404 |
Enzyme_unclassified | ALOX12 | Arachidonate 12-lipoxygenase | P18054 | CHEMBL3687 |
Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
Lysine demethylase | KDM4E | Lysine-specific demethylase 4D-like | B2RXH2 | CHEMBL1293226 |
Miscellaneous ion channel | BCL2 | Apoptosis regulator Bcl-2 | P10415 | CHEMBL4860 |
Nuclear hormone receptor subfamily 1 group C | PPARA | Peroxisome proliferator-activated receptor alpha | Q07869 | CHEMBL239 |
Nuclear hormone receptor subfamily 1 group F | RORC | Nuclear receptor ROR-gamma | P51449 | CHEMBL1741186 |
Nuclear hormone receptor subfamily 1 group H | NR1H4 | Bile acid receptor FXR | Q96RI1 | CHEMBL2047 |
Peptide receptor (family A GPCR) | NPSR1 | Neuropeptide S receptor | Q6W5P4 | CHEMBL5162 |
Protein Kinase | MET | Hepatocyte growth factor receptor | P08581 | CHEMBL3717 |
Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
Protein Kinase | CDK1 | Cyclin-dependent kinase 1 | P06493 | CHEMBL308 |
Protein Kinase | PIM1 | Serine/threonine-protein kinase PIM1 | P11309 | CHEMBL2147 |
Protein Kinase | AXL | Tyrosine-protein kinase receptor UFO | P30530 | CHEMBL4895 |
Protein Kinase | KDR | Vascular endothelial growth factor receptor 2 | P35968 | CHEMBL279 |
Protein Kinase | IGF1R | Insulin-like growth factor I receptor | P08069 | CHEMBL1957 |
Protein Kinase | AURKB | Serine/threonine-protein kinase Aurora-B | Q96GD4 | CHEMBL2185 |
Small molecule receptor (family A GPCR) | FFAR1 | Free fatty acid receptor 1 | O14842 | CHEMBL4422 |
Small molecule receptor (family A GPCR) | FFAR4 | G-protein coupled receptor 120 | Q5NUL3 | CHEMBL5339 |
Small molecule receptor (family A GPCR) | ADRA2B | Alpha-2b adrenergic receptor | P18089 | CHEMBL1942 |
Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
Transferase | FUT7 | Alpha-(1,3)-fucosyltransferase 7 | Q11130 | CHEMBL3596077 |
Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
Unclassified | FABP3 | Fatty acid binding protein muscle | P05413 | CHEMBL3344 |
Unclassified | FABP4 | Fatty acid binding protein adipocyte | P15090 | CHEMBL2083 |
Unclassified | FABP5 | Fatty acid binding protein epidermal | Q01469 | CHEMBL3674 |
GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|
BP | GO:0009987; cellular process | GO:0043066; negative regulation of apoptotic process | 1.750E-08 | 2.382E-05 | ALOX12, AURKB, AXL, BCL2, CDK1, FFAR4, IGF1R, KDR, LMNA, NFKB1, NR1H4, PIM1 |
MF | GO:0005488; binding | GO:0005504; fatty acid binding | 1.539E-07 | 1.457E-04 | FABP3, FABP4, FABP5, FFAR4 |
BP | GO:0065007; biological regulation | GO:0048878; chemical homeostasis | 5.234E-07 | 3.930E-04 | ALOX12, BCL2, CA2, CA7, FABP3, FABP4, FFAR1, MET, NOX4, NPSR1, NR1H4 |
MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 2.443E-06 | 1.297E-03 | CA14, CA2, CA7 |
BP | GO:0008152; metabolic process | GO:2001303; lipoxin A4 biosynthetic process | 3.190E-06 | 1.478E-03 | ALOX12, ALOX15 |
MF | GO:0003824; catalytic activity | GO:0047977; hepoxilin-epoxide hydrolase activity | 3.190E-06 | 1.478E-03 | ALOX12, ALOX15 |
BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 9.558E-06 | 3.202E-03 | CA2, CA7 |
BP | GO:0019740; nitrogen utilization | GO:0006808; regulation of nitrogen utilization | 9.558E-06 | 3.202E-03 | BCL2, NR1H4 |
MF | GO:0003824; catalytic activity | GO:0004052; arachidonate 12-lipoxygenase activity | 9.558E-06 | 3.202E-03 | ALOX12, ALOX15 |
MF | GO:0003824; catalytic activity | GO:0051120; hepoxilin A3 synthase activity | 9.558E-06 | 3.202E-03 | ALOX12, ALOX15 |
MF | Unclassified; | GO:0004872; receptor activity | 1.029E-05 | 3.249E-03 | ADRA2B, AXL, FFAR1, FFAR4, FLT3, IGF1R, KDR, MET, NPSR1, NR1H4, PPARA, RORC |
BP | GO:0008152; metabolic process | GO:0019433; triglyceride catabolic process | 1.220E-05 | 3.638E-03 | FABP3, FABP4, FABP5 |
BP | GO:0050896; response to stimulus | GO:0009725; response to hormone | 1.850E-05 | 5.100E-03 | ALPL, BCL2, CA2, FABP3, FFAR4, FLT3, NFKB1, PPARA |
BP | GO:0008152; metabolic process | GO:0018108; peptidyl-tyrosine phosphorylation | 2.014E-05 | 5.334E-03 | AXL, FLT3, IGF1R, KDR, MET |
BP | GO:0002376; immune system process | GO:0030098; lymphocyte differentiation | 2.121E-05 | 5.498E-03 | AXL, BCL2, FLT3, FUT7, RORC |
BP | GO:0008152; metabolic process | GO:0046777; protein autophosphorylation | 2.591E-05 | 6.132E-03 | AURKB, FLT3, IGF1R, KDR, PIM1 |
MF | GO:0005488; binding | GO:0008144; drug binding | 3.008E-05 | 6.752E-03 | AURKB, AXL, CDK1, CYP1B1, FLT3, IGF1R, KDR, MET, NOX4, PIM1, PPARA, RECQL |
BP | GO:0008152; metabolic process | GO:0051122; hepoxilin biosynthetic process | 3.179E-05 | 6.922E-03 | ALOX12, ALOX15 |
BP | GO:0008152; metabolic process | GO:0072593; reactive oxygen species metabolic process | 3.383E-05 | 7.210E-03 | ALOX12, BCL2, CYP1B1, NOX4 |
BP | Unclassified; | GO:2000021; regulation of ion homeostasis | 3.444E-05 | 7.210E-03 | BCL2, CA2, CA7, KDR, NPSR1 |
BP | GO:0009987; cellular process | GO:0071407; cellular response to organic cyclic compound | 3.588E-05 | 7.440E-03 | ALPL, CYP1B1, FLT3, NFKB1, NOX4, RORC |
Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|---|
09150 Organismal Systems | 09152 Endocrine system | hsa03320 | PPAR signaling pathway | 6.266E-06 | 3.697E-04 | FABP3, FABP4, FABP5, PPARA |
09100 Metabolism | 09102 Energy metabolism | hsa00910 | Nitrogen metabolism | 3.283E-06 | 3.697E-04 | CA2, CA7, CA14 |
09160 Human Diseases | 09161 Cancers | hsa05221 | Acute myeloid leukemia | 1.346E-04 | 4.641E-03 | FLT3, PIM1, NFKB1 |
09160 Human Diseases | 09161 Cancers | hsa05206 | MicroRNAs in cancer | 1.573E-04 | 4.641E-03 | PIM1, BCL2, CYP1B1, MET, NFKB1 |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04151 | PI3K-Akt signaling pathway | 2.983E-04 | 5.867E-03 | KDR, BCL2, MET, NFKB1, IGF1R |
09160 Human Diseases | 09161 Cancers | hsa05200 | Pathways in cancer | 5.973E-04 | 7.573E-03 | FLT3, BCL2, MET, NFKB1, IGF1R |
09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04510 | Focal adhesion | 4.139E-04 | 6.976E-03 | KDR, BCL2, MET, IGF1R |
09160 Human Diseases | 09161 Cancers | hsa05202 | Transcriptional misregulation in cancer | 2.672E-04 | 5.867E-03 | FLT3, MET, NFKB1, IGF1R |
09160 Human Diseases | 09161 Cancers | hsa05215 | Prostate cancer | 5.029E-04 | 7.418E-03 | BCL2, NFKB1, IGF1R |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04014 | Ras signaling pathway | 6.420E-04 | 7.573E-03 | KDR, MET, NFKB1, IGF1R |
09160 Human Diseases | 09166 Endocrine and metabolic diseases | hsa04933 | AGE-RAGE signaling pathway in diabetic complications | 7.275E-04 | 7.573E-03 | PIM1, BCL2, NFKB1 |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04066 | HIF-1 signaling pathway | 7.702E-04 | 7.573E-03 | BCL2, NFKB1, IGF1R |
ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
---|---|---|---|
C00-D49: Neoplasms | Leukemia | C90-C95 | FLT3; BCL2; |
C00-D49: Neoplasms | Liver cancer | C22 | IGF1R; KDR; |
C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | KDR; |
I00-I99: Diseases of the circulatory system | Heart disease | I00-I52 | MET; |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | FFAR1; |
C00-D49: Neoplasms | Solid tumours | C00-D48 | MET; AURKB; IGF1R; KDR; FLT3; |
C00-D49: Neoplasms | Squamous cell cancer of head and neck | NA | KDR; |
NA: NA | Edema | NA | CA2; |
C00-D49: Neoplasms | Gastrointestinal cancers | C15-C26 | KDR; |
Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Genetic disease | Q00-Q99 | ALPL; |
I00-I99: Diseases of the circulatory system | Angiogenesis disorder | I00-I99 | KDR; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2; |
C00-D49: Neoplasms | Glioblastoma | NA | FLT3; |
L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | FLT3; BCL2; |
G00-G99: Diseases of the nervous system G00-G99 | Amyotrophic lateral sclerosis | G12.2 | BCL2; |
NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3; |
L00-L99: Diseases of the skin and subcutaneous tissue | Psoriatic disorder | L40 | IGF1R; |
C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3; |
C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | KDR; |
C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | KDR; |
C00-D49: Neoplasms | Metastatic HER2-negative gastric cancer | NA | MET; |
G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | ADRA2B; |
C00-D49: Neoplasms | AML | NA | KDR; FLT3; |
C00-D49: Neoplasms | Prostate cancer | C61 | FLT3; BCL2; |
C00-D49: Neoplasms | Metastatic breast cancer | C50 | KDR; |
C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | KDR; |
J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3; |
C00-D49: Neoplasms | Advanced solid tumor | C00-C75, C7A, C7B | MET; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | ADRA2B; |
C00-D49: Neoplasms | Metastasis | C00-C97 | AXL; |
C00-D49: Neoplasms | Renal cancer | C64 | KDR; |
C00-D49: Neoplasms | Renal cell carcinoma | NA | KDR; |
K00-K95: Diseases of the digestive system | Chemotherapy-induced mucositis | K12.3 | MET; |
I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | NPSR1; |
A00-B99: Certain infectious and parasitic diseases | Anthelmintic | B89 | ALPL; |
C00-D49: Neoplasms | Medullary thyroid cancer | C73 | KDR; |
C00-D49: Neoplasms | Advanced melanoma | C43 | BCL2; |
C00-D49: Neoplasms | Advanced renal cell carcinoma | C64 | KDR; |
C00-D49: Neoplasms | Non-small-cell lung cancer | NA | KDR; |
C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | MET; IGF1R; KDR; AXL; |
E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | FFAR1; |
C00-D49: Neoplasms | Malignant adrenal gland cancer | C74.0 | IGF1R; |
H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA2; |
E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | NFKB1; FFAR1; |
C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3; |
C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | AURKB; FLT3; |
I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | KDR; |
H00-H59: Diseases of the eye and adnexa | Graves' ophthalmopathy | H06.2 | IGF1R; |
K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; |
C00-D49: Neoplasms | Ovarian cancer | C56 | KDR; |
C00-D49: Neoplasms | CLL | NA | FLT3; |
G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | CDK1; IGF1R; |
C00-D49: Neoplasms | Gliosarcoma | NA | FLT3; |
C00-D49: Neoplasms | Melanoma | C43 | KDR; |
C00-D49: Neoplasms | Thyroid cancer | C73 | KDR; |
C00-D49: Neoplasms | Cutaneous Melanoma | C43-C44 | KDR; |
C00-D49: Neoplasms | Breast cancer | C50 | CDK1; IGF1R; KDR; FLT3; BCL2; |
C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | MET; IGF1R; KDR; |
C00-D49: Neoplasms | Chronic lymphocytic leukaemia | C91 | BCL2; |
I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2; |
C00-D49: Neoplasms | Cancer | C00-C96 | PIM1; MET; CDK1; IGF1R; KDR; NFKB1; FLT3; BCL2; |
C00-D49: Neoplasms | Advanced malignancies | C00-C96 | KDR; |
C00-D49: Neoplasms | Biliary cancer | C22, C24 | KDR; |
I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2; |
C00-D49: Neoplasms | Multiple myeloma | C90 | IGF1R; BCL2; |
G00-G99: Diseases of the nervous system G00-G99 | Motor neurone disease | G12.2 | IGF1R; |
C00-D49: Neoplasms | Glioma | C71 | KDR; |
C00-D49: Neoplasms | Peritoneal cavity cancer | NA | KDR; |
A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3; |
L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | MET; |
C00-D49: Neoplasms | Gastric cancer | C16 | KDR; |
C00-D49: Neoplasms | Colorectal cancer | C18-C21 | IGF1R; KDR; FLT3; |
C00-D49: Neoplasms | Colon cancer | C50 | FLT3; ALPL; |
NA: NA | Hematopoietic stem cell transplantation | NA | FLT3; |
C00-D49: Neoplasms | Hematological malignancies | C81-C86 | AURKB; |
C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3; |
C00-D49: Neoplasms | Fallopian tube cancer | C57.0, D28.2 | KDR; |
E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | IGF1R; |
C00-D49: Neoplasms | Pancreatic cancer | C25 | KDR; FLT3; |
K00-K95: Diseases of the digestive system | Liver disease | K70-K77 | MET; |
C00-D49: Neoplasms | Lymphoma | C81-C86 | BCL2; |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Growth failure | R62.8 | IGF1R; |
NA: NA | GIST | NA | FLT3; |